These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

754 related items for PubMed ID: 19489653

  • 1. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Oldfield V, Plosker GL.
    BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
    [Abstract] [Full Text] [Related]

  • 2. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG, Halilovic J, Stan-Ugbene O.
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [Abstract] [Full Text] [Related]

  • 3. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J.
    J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
    [Abstract] [Full Text] [Related]

  • 4. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

  • 5. Golimumab (simponi) for inflammatory arthritis.
    Med Lett Drugs Ther; 2009 Jul 13; 51(1316):55-6. PubMed ID: 19590489
    [No Abstract] [Full Text] [Related]

  • 6. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A.
    Ann Rheum Dis; 2015 Mar 13; 74(3):538-46. PubMed ID: 24344160
    [Abstract] [Full Text] [Related]

  • 7. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Voulgari PV.
    Expert Rev Clin Immunol; 2010 Sep 13; 6(5):721-33. PubMed ID: 20828280
    [Abstract] [Full Text] [Related]

  • 8. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME, Deodhar A, Schwartzman S, Chakravarty SD, Hsia EC, Leu JH, Zhou Y, Lo KH, Kavanaugh A.
    Arthritis Res Ther; 2022 Mar 21; 24(1):73. PubMed ID: 35313978
    [Abstract] [Full Text] [Related]

  • 9. Golimumab: A novel anti-TNF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Campas-Moya C.
    Drugs Today (Barc); 2010 Jan 21; 46(1):13-22. PubMed ID: 20200692
    [Abstract] [Full Text] [Related]

  • 10. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.
    Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU, GO-FORWARD Study.
    Ann Rheum Dis; 2009 Jun 21; 68(6):789-96. PubMed ID: 19066176
    [Abstract] [Full Text] [Related]

  • 11. Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
    Rossini M, Viapiana O, Orsolini G, Fracassi E, Idolazzi L, Gatti D, Adami S, Govoni M.
    Reumatismo; 2015 Mar 31; 66(4):285-303. PubMed ID: 25829189
    [Abstract] [Full Text] [Related]

  • 12. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Weinstein CLJ, Meehan AG, Lin J, Briscoe SD, Govoni M.
    Clin Rheumatol; 2023 Dec 31; 42(12):3397-3405. PubMed ID: 37751000
    [Abstract] [Full Text] [Related]

  • 13. Golimumab for the treatment of psoriatic arthritis.
    Yang H, Epstein D, Bojke L, Craig D, Light K, Bruce I, Sculpher M, Woolacott N.
    Health Technol Assess; 2011 May 31; 15 Suppl 1():87-95. PubMed ID: 21609657
    [Abstract] [Full Text] [Related]

  • 14. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
    Rotar Ž, Tomšič M, Praprotnik S, Slovenian Rheumatologists.
    Clin Rheumatol; 2019 Feb 31; 38(2):297-305. PubMed ID: 30324406
    [Abstract] [Full Text] [Related]

  • 15. The efficacy and safety of golimumab in the treatment of arthritis.
    Fleischmann R.
    Expert Opin Biol Ther; 2010 Jul 31; 10(7):1131-43. PubMed ID: 20504106
    [Abstract] [Full Text] [Related]

  • 16. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
    Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A.
    Arthritis Rheum; 2009 Apr 31; 60(4):976-86. PubMed ID: 19333944
    [Abstract] [Full Text] [Related]

  • 17. Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    Leu JH, Adedokun OJ, Gargano C, Hsia EC, Xu Z, Shankar G.
    Rheumatology (Oxford); 2019 Mar 01; 58(3):441-446. PubMed ID: 30412238
    [Abstract] [Full Text] [Related]

  • 18. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
    Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P.
    Arthritis Rheum; 2010 Apr 01; 62(4):917-28. PubMed ID: 20131276
    [Abstract] [Full Text] [Related]

  • 19. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
    Chovel-Sella A, Karplus R, Sella T, Amital H.
    Isr Med Assoc J; 2012 Jun 01; 14(6):390-4. PubMed ID: 22891404
    [Abstract] [Full Text] [Related]

  • 20. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK.
    Rheumatology (Oxford); 2013 Oct 01; 52(10):1845-55. PubMed ID: 23838027
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.